Ablexis Announces Multi-Target Licensing Agreement with Zai Lab (US)

Ablexis grants rights to use the AlivaMab™ Mouse platform for
research, development and potential commercialization of antibodies

SAN DIEGO–(BUSINESS WIRE)–Ablexis, LLC, a biopharmaceutical company focused on licensing its
AlivaMab Mouse technology for antibody drug discovery, today announced a
license agreement with Zai Lab (US), LLC. The non-exclusive license
grants Zai rights to use the AlivaMab Mouse for antibody drug discovery
and development. Financial terms of the license include upfront
payments, development milestones and a revenue share on product sales.

“Ablexis is pleased that the skilled and experienced research team at
Zai Lab (US) has selected AlivaMab Mouse as a platform for their
antibody drug discovery efforts,” said Larry Green, Ph.D., Chief
Executive Officer of Ablexis, LLC. “Over and over, research teams with
track records of success in bringing antibody drugs from discovery to
clinical development and to market are choosing a transgenic mouse
platform as the foundation for their human antibody drug discovery
efforts, and, moreover, they are choosing AlivaMab Mouse. Ablexis’ new,
flexible licensing model continues expanding access to AlivaMab Mouse,
the best-in-class platform for successful antibody drug discovery and
development.”

About Ablexis, LLC
Ablexis, LLC created and commercializes
the AlivaMab Mouse technology, a unique, patented next generation
transgenic mouse platform for human therapeutic antibody discovery.
Ablexis has non-exclusively licensed the AlivaMab Mouse technology to
multiple companies, including global pharmaceutical companies, public
and private biotechnology companies and other entities. Ablexis
continues making the AlivaMab Mouse available via non-exclusive
licenses. For more information, visit www.ablexis.com.
For inquiries about licensing AlivaMab Mouse, contact us at [email protected].

Contacts

Media Contact:
Christine Quern
[email protected]
617-650-8497